IRD (Opus Genetics) Other Current Receivables: $0.98 Mil (As of Mar. 2026)


IRD Opus Genetics Inc IRD
24 GF Score
Price $4.18
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics Other Current Receivables?

Opus Genetics IRD +1.70% 24 Other Current Receivables is $0.98 Mil as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Opus Genetics's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.98 Mil.

Opus Genetics's quarterly Other Current Receivables declined from Sep. 2025 ($1.36 Mil) to Dec. 2025 ($1.17 Mil) but then stayed the same from Dec. 2025 ($1.17 Mil) to Mar. 2026 ($0.98 Mil).

Opus Genetics's annual Other Current Receivables increased from Dec. 2023 ($1.41 Mil) to Dec. 2024 ($2.21 Mil) but then declined from Dec. 2024 ($2.21 Mil) to Dec. 2025 ($1.17 Mil).

Opus Genetics Other Current Receivables Related Terms

Opus Genetics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Opus Genetics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics Other Current Receivables Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.00 3.55 1.41 2.21 1.17

Opus Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.18 1.36 1.17 0.98
IRD
24GF Score
Opus Genetics Inc IRD
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.98 Mil mean?
Opus Genetics (IRD) has a Other Current Receivables of $0.98 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Opus Genetics and its competitors.
Is Opus Genetics' Other Current Receivables too high?
Opus Genetics' current Other Current Receivables is $0.98 Mil. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Other Current Receivables compare to PALI and VSTM?
Opus Genetics' Other Current Receivables of $0.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Opus Genetics and its competitors. Opus Genetics's current Other Current Receivables is $0.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.18 — trading 1029.7% above its estimated fair value. The current Other Current Receivables is $0.98 Mil. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Opus Genetics (IRD), the current Other Current Receivables is $0.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $4.18 is trading 1029.7% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • Other Current Receivables: $0.98 Mil
  • GF Value™: $0.37 vs. price of $4.18 (1029.7% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.18
Price
$0.37
GF Value